MX389346B - Formulaciones de anticuerpos monoclonales de alta concentración. - Google Patents

Formulaciones de anticuerpos monoclonales de alta concentración.

Info

Publication number
MX389346B
MX389346B MX2018004968A MX2018004968A MX389346B MX 389346 B MX389346 B MX 389346B MX 2018004968 A MX2018004968 A MX 2018004968A MX 2018004968 A MX2018004968 A MX 2018004968A MX 389346 B MX389346 B MX 389346B
Authority
MX
Mexico
Prior art keywords
formulation
monoclonal antibody
antibody formulations
high concentration
making
Prior art date
Application number
MX2018004968A
Other languages
English (en)
Inventor
Mayumi N Bowen
Nicholas J Armstrong
Yuh-Fun Maa
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48471141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX389346(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX389346B publication Critical patent/MX389346B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formulaciones de anticuerpos de alta concentración adecuadas para administración subcutánea, es decir mediante una jeringa previamente llena. En particular, describe una formulación que comprende un anticuerpo monoclonal seco por rocío a una concentración de aproximadamente 200 mg/mL o más suspendido en un vehículo de suspensión no acuoso en donde la viscosidad del vehículo de suspensión es menor a aproximadamente 20 centipoises. También se describen: un dispositivo de administración subcutánea con la formulación ahí, un método para elaborar la formulación, un método para producir un artículo de manufactura que comprende la formulación en suspensión, el uso de la formulación en la preparación de un medicamento, y un método para tratar a un paciente con la formulación.
MX2018004968A 2012-05-18 2013-05-17 Formulaciones de anticuerpos monoclonales de alta concentración. MX389346B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649146P 2012-05-18 2012-05-18
PCT/US2013/041532 WO2013173687A1 (en) 2012-05-18 2013-05-17 High-concentration monoclonal antibody formulations

Publications (1)

Publication Number Publication Date
MX389346B true MX389346B (es) 2025-03-20

Family

ID=48471141

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004968A MX389346B (es) 2012-05-18 2013-05-17 Formulaciones de anticuerpos monoclonales de alta concentración.
MX2014013868A MX355611B (es) 2012-05-18 2013-05-17 Formulaciones de anticuerpos monoclonales de alta concentracion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014013868A MX355611B (es) 2012-05-18 2013-05-17 Formulaciones de anticuerpos monoclonales de alta concentracion.

Country Status (23)

Country Link
US (5) US20130309226A1 (es)
EP (2) EP3427721B1 (es)
JP (3) JP6254581B2 (es)
KR (2) KR102201607B1 (es)
CN (2) CN108187043A (es)
AU (3) AU2013262611B2 (es)
BR (1) BR112014028600B1 (es)
CA (1) CA2873646C (es)
ES (2) ES3025360T3 (es)
HK (1) HK1257554A1 (es)
HR (2) HRP20250525T1 (es)
HU (1) HUE071647T2 (es)
IL (3) IL235716B (es)
MX (2) MX389346B (es)
MY (1) MY188825A (es)
NZ (3) NZ725654A (es)
PL (2) PL2849723T3 (es)
RU (1) RU2711089C2 (es)
SG (2) SG11201407512VA (es)
SI (1) SI2849723T1 (es)
TR (1) TR201810930T4 (es)
WO (1) WO2013173687A1 (es)
ZA (2) ZA201408651B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342675B (es) 2011-03-10 2016-10-07 Xeris Pharmaceuticals Inc Formulaciones estables para inyeccion parenteral de farmacos de peptido.
EP2790681B9 (en) 2011-11-18 2023-07-26 Regeneron Pharmaceuticals, Inc. Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying
AU2013262611B2 (en) 2012-05-18 2018-03-01 Genentech, Inc. High-concentration monoclonal antibody formulations
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
CN106536559B (zh) * 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
KR102428675B1 (ko) * 2014-08-06 2022-08-02 엑스에리스 파머수티클스, 인크. 페이스트의 피내 및／또는 피하 주사를 위한 주사기, 키트, 및 방법
JP6716577B2 (ja) 2014-10-01 2020-07-01 イーグル・バイオロジクス・インコーポレイテッドＥａｇｌｅ Ｂｉｏｌｏｇｉｃｓ， Ｉｎｃ． 粘度低下物質を含有する、多糖および核酸の調合薬
EP3250596A1 (en) 2015-01-28 2017-12-06 Pfizer Inc Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CN107427577A (zh) 2015-03-31 2017-12-01 韦斯夸尔德有限公司 具有蛋白酶可切割接头的肽构建体
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2017032686A1 (en) * 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
US20170056504A1 (en) * 2015-09-02 2017-03-02 Kenneth I. Kohn Method of extending half-life of crystaline antibodies
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN120884568A (zh) 2015-09-30 2025-11-04 诺瓦利克有限责任公司 半氟化化合物和其组合物
EA201891164A1 (ru) 2015-12-16 2018-11-30 Ридженерон Фармасьютикалз, Инк. Композиции и способы получения белковых микрочастиц
SG11201807402PA (en) 2016-03-31 2018-09-27 Vhsquared Ltd Compositions
WO2018067987A1 (en) * 2016-10-06 2018-04-12 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
CN110062765A (zh) 2016-10-31 2019-07-26 维克特拉有限公司 包括il-13抗体的可吸入粉末组合物
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
ES2982668T3 (es) 2017-06-02 2024-10-17 Xeris Pharmaceuticals Inc Formulaciones de fármacos de moléculas pequeñas resistentes a la precipitación
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
AU2019244150B2 (en) * 2018-03-30 2024-11-28 Tomoki Todo Swelling-suppressive oncolytic virus
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
SG11202101980VA (en) 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
WO2020071876A1 (ko) * 2018-10-04 2020-04-09 삼성바이오에피스 주식회사 점도가 감소된 고농도 트라스투주맙 또는 이의 항원 결합 단편 안정화 제제
CN113164378A (zh) * 2018-11-21 2021-07-23 瑞泽恩制药公司 高浓度蛋白质制剂
CN113661006A (zh) 2019-02-05 2021-11-16 林迪生物科学公司 分离的细胞培养物组分以及用于从液体细胞培养基中分离其的方法
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
MA55205A (fr) * 2019-03-06 2022-01-12 Zoetis Services Llc Formulations injectables prêtes à l'emploi
JP7654561B2 (ja) 2019-04-11 2025-04-01 アール．ピー． シェーラー テクノロジーズ エルエルシー 浸透性が低いタンパク質、ペプチド、及び小分子の経口送達用の製剤
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
WO2020257407A1 (en) 2019-06-19 2020-12-24 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
MX2021015761A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
MX2021015762A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Composiciones.
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2021105392A1 (en) * 2019-11-27 2021-06-03 Novaliq Gmbh Suspension comprising a protein particle suspended in a non-aqueous vehicle
CN113082203B (zh) * 2020-01-09 2023-10-20 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
IL299508A (en) 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Anti-asgr1 antibody conjugates and uses thereof
EP4182025A1 (en) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
WO2023013933A1 (ko) 2021-08-05 2023-02-09 주식회사 엘지에너지솔루션 전극 조립체, 원통형 배터리 셀 및 이를 포함하는 배터리 팩 및 자동차
US20250219272A1 (en) 2021-08-05 2025-07-03 Lg Energy Solution, Ltd. Electrode assembly, battery, and battery pack and vehicle including the same
KR20240057428A (ko) * 2021-09-09 2024-05-02 엑스에리스 파머수티클스, 인크. 주사 가능한 고농도 약제학적 제형 및 이의 제조 및 사용 방법
EP4511062A1 (en) * 2022-04-22 2025-02-26 Eirgenix, Inc. Pharmaceutical compositons containing anti-her2 antibody for subcutaneous administration
WO2025117847A1 (en) * 2023-12-01 2025-06-05 Serán BioScience, LLC Methods and systems for injectable formulations
WO2025160310A1 (en) * 2024-01-24 2025-07-31 Serán BioScience, LLC High dosage injectable bevacizumab formulations and methods

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
GB1225979A (es) 1967-03-23 1971-03-24
US3639587A (en) 1969-11-07 1972-02-01 Eastman Kodak Co Medicinal compositions for administration to animals and process for administering same
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
DE2949849A1 (de) 1979-12-12 1981-06-19 A. Nattermann & Cie GmbH, 5000 Köln Phosphatidylcholin-loesungen
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
WO1989012463A1 (en) 1988-06-21 1989-12-28 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DK0656789T3 (da) 1992-08-21 1998-08-24 Genentech Inc Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse.
DE69405251T2 (de) 1993-12-10 1998-02-05 Genentech Inc Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika
MX9602818A (es) 1994-01-18 1997-06-28 Genentech Inc Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
WO1995023865A1 (en) 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
PT1516628E (pt) * 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP4864175B2 (ja) 1996-01-23 2012-02-01 ジェネンテック， インコーポレイテッド 発作に関する抗―ｃｄ１８抗体
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DK0941344T3 (da) 1996-11-27 2004-09-27 Genentech Inc Humaniserede anti-CD11a-antistoffer
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
JP4028237B2 (ja) 1999-10-29 2007-12-26 ジェネンテック・インコーポレーテッド 抗前立腺幹細胞抗原（ｐｓｃａ）抗体組成物及び使用方法
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US20030198619A1 (en) 2001-12-19 2003-10-23 Dong Liang C. Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
CA2475388A1 (en) 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
ES2575547T3 (es) 2003-02-01 2016-06-29 Tanox, Inc. Anticuerpos anti-IgE de humano de alta afinidad
HRP20050934B1 (hr) * 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
US20070032465A1 (en) 2003-05-29 2007-02-08 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha
KR20160014775A (ko) * 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005112893A1 (en) 2004-05-12 2005-12-01 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
KR101231856B1 (ko) 2004-08-12 2013-02-08 큐피에스 엘엘씨 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060216242A1 (en) 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8226926B2 (en) * 2005-05-09 2012-07-24 Biosphere Medical, S.A. Compositions and methods using microspheres and non-ionic contrast agents
CN101378782A (zh) 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd ANTIBODY-CONTAINING STABILIZING PREPARATION
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
WO2008092084A2 (en) * 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
RU2500686C2 (ru) 2007-03-22 2013-12-10 Дженентек, Инк. АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE
US7611705B2 (en) 2007-06-15 2009-11-03 National Cheng Kung University Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
BRPI0907186A2 (pt) 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
JP5711138B2 (ja) * 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
JP5685193B2 (ja) * 2008-11-19 2015-03-18 メリアル リミテッド セフチオフルおよびケトプロフェンとまたはセフチオフルとベンジルアルコールとを含む製剤
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
MX359879B (es) * 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CN103096934A (zh) 2010-03-09 2013-05-08 詹森生物科技公司 非水性高浓度低粘度混悬剂
JP6209446B2 (ja) * 2010-06-02 2017-10-04 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
AU2013262611B2 (en) 2012-05-18 2018-03-01 Genentech, Inc. High-concentration monoclonal antibody formulations

Also Published As

Publication number Publication date
NZ737862A (en) 2020-01-31
AU2020204588A1 (en) 2020-07-30
JP7015156B2 (ja) 2022-02-02
US20200087415A1 (en) 2020-03-19
TR201810930T4 (tr) 2018-08-27
KR20150009593A (ko) 2015-01-26
CA2873646C (en) 2022-04-26
MX355611B (es) 2018-04-25
JP2020059716A (ja) 2020-04-16
PL2849723T3 (pl) 2018-10-31
US20130309226A1 (en) 2013-11-21
EP2849723A1 (en) 2015-03-25
BR112014028600A8 (pt) 2021-09-14
ZA202109290B (en) 2023-07-26
NZ725654A (en) 2018-04-27
HK1257554A1 (zh) 2019-10-25
AU2013262611A1 (en) 2015-01-15
MY188825A (en) 2022-01-06
KR102201607B1 (ko) 2021-01-12
CN104427974A (zh) 2015-03-18
SG10201709555SA (en) 2017-12-28
BR112014028600B1 (pt) 2022-11-22
MX2014013868A (es) 2015-05-15
EP3427721A1 (en) 2019-01-16
IL235716B (en) 2019-08-29
IL235716A0 (en) 2015-01-29
JP2018090581A (ja) 2018-06-14
JP2015520164A (ja) 2015-07-16
ZA201408651B (en) 2022-09-28
US20160176986A1 (en) 2016-06-23
BR112014028600A2 (pt) 2017-08-01
HK1207826A1 (en) 2016-02-12
JP6254581B2 (ja) 2017-12-27
HUE071647T2 (hu) 2025-09-28
IL282805A (en) 2021-06-30
PL3427721T3 (pl) 2025-07-14
SG11201407512VA (en) 2014-12-30
AU2018203876B2 (en) 2020-04-09
RU2711089C2 (ru) 2020-01-15
HRP20250525T1 (hr) 2025-06-20
US20240425615A1 (en) 2024-12-26
KR102326359B1 (ko) 2021-11-12
CN104427974B (zh) 2018-03-23
RU2019142698A (ru) 2020-05-27
NZ701915A (en) 2016-11-25
KR20210103388A (ko) 2021-08-23
US20210292435A1 (en) 2021-09-23
IL268280B (en) 2021-05-31
WO2013173687A1 (en) 2013-11-21
AU2018203876A1 (en) 2018-06-21
ES2682761T3 (es) 2018-09-21
SI2849723T1 (sl) 2018-09-28
ES3025360T3 (en) 2025-06-09
CA2873646A1 (en) 2013-11-21
CN108187043A (zh) 2018-06-22
AU2013262611B2 (en) 2018-03-01
EP3427721B1 (en) 2025-03-19
HRP20181211T1 (hr) 2018-10-05
EP3427721C0 (en) 2025-03-19
US12018091B2 (en) 2024-06-25
EP2849723B1 (en) 2018-05-02
IL268280A (en) 2019-09-26
RU2014151359A (ru) 2016-07-10

Similar Documents

Publication Publication Date Title
MX389346B (es) Formulaciones de anticuerpos monoclonales de alta concentración.
MX2012010114A (es) Formulaciones concentradas de proteina y usos de las mismas.
NZ707377A (en) Combination therapy methods for treating proliferative diseases
MX2013005341A (es) Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
EA033373B1 (ru) Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему
MX354811B (es) Lipidos de aminoacidos de transporte dirigido.
MY152304A (en) An insulin conjugate using an immunoglobulin fragment
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
JP2016539921A5 (es)
NZ702342A (en) Pharmaceutical formulation
MY180502A (en) Compound of glycosaminoglycan, preparation method and use thereof
PH12015502556A1 (en) Modified release formulation
HRP20200704T1 (hr) Vodena formulacija koja sadrži paracetamol i ibuprofen
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
EA201592040A1 (ru) Иммуногенная композиция для применения в терапии
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
MX374771B (es) Formulación parenteral de esmolol.
MX383557B (es) Formulaciones inyectables de paracetamol.
PL414785A1 (pl) Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną
RU2012110137A (ru) Способ лечения инсулинорезистентности
AR088093A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y acetato de glatiramer